The purpose of this activity is to equip pharmacists and pharmacy technicians with information to help determine how to provide safe and effective adjunctive therapy options for the patients with AWS. Benzodiazepine agents have been used as the standard of care for the prophylaxis and treatment of all phases of AWS. While most patients suffering from AWS will respond to benzodiazepines, there is a subgroup of patients with severe AWS who are refractory and require additional therapies. Additionally, benzodiazepines have drawbacks including significant cognitive and neurological side effects. Recent literature has shown that using a multimodal approach to managing benzodiazepine-refractory patients appears beneficial in improving symptoms. This presentation reviews several clinical trials evaluating the use of adjunctive therapies for patients with AWS. Understanding the place for adjunctive therapies in the management of patients with AWS will allow pharmacists to provide evidence-based recommendations to the medical team.